Advancing Suspension Manufacturing of Stem Cell–Derived Islets in Vertical Wheel Bioreactors for Scalable Diabetes Therapy: An Upstate Medical Initiative.
ON DEMAND: Dr Nidheesh Dedheech PhD, April 2, 2026
ON DEMAND VIDEO:
📺 [Watch the full talk here →]
💬 Key Quote
“We really need to give these cells a mimicking environment — as a normal endogenous environment that happens in the body. Circadian rhythm is one of the very critical things that imparts glucose sensing mechanism and maturity to these cells.” — Dr. Nidheesh Dadheech
🔬 Foundational Insights as They Apply to T1D
The promise of stem cell-derived islet therapy for T1D has always rested on two pillars: making enough cells, and making them work. Most of the field’s attention has gone to the second pillar — functional maturity, immune evasion, engraftment — while the first has remained an underappreciated bottleneck. You cannot transplant what you cannot manufacture at scale, and current protocols that rely on planar plates and labor-intensive multi-vessel pooling simply cannot produce the 1.5 to 2 million islet equivalents per patient needed to achieve insulin independence. Dr. Dadheech’s work addresses this head-on.
By adapting vertical wheel bioreactor technology — already FDA-compliant for cell therapy production — to a fully suspension-based differentiation protocol, his lab has demonstrated a path to clinical-scale islet manufacturing from a single vessel. The approach is not just about volume. Full 3D suspension throughout both expansion and differentiation phases produces cells that are more homogeneous, better matured, and more functionally responsive than their 2D counterparts — while generating 12-fold higher islet equivalent yields even at the modest 0.5-liter scale. Projected to 3 liters, the math begins to reach what a clinical program actually needs.
Critically, this platform is being built from the ground up to support autologous therapy — reprogramming patient-derived iPSCs and differentiating them back into islet-like cells — with the explicit goal of eliminating immunosuppression, at least in T2D and pancreatogenic diabetes, and potentially in T1D as immune evasion strategies continue to mature.
🎯 Core Premise
Scalable, GMP-compatible, fully suspension-based manufacturing of iPSC-derived islets using vertical wheel bioreactors is not just feasible — it is the necessary infrastructure for personalized cell therapy to move from proof-of-concept to clinic. Solving the manufacturing problem is as important as solving the biology problem, and the two must be co-developed if stem cell-derived islet therapy is ever going to reach patients at meaningful scale.
🌟 Why This Talk Matters to T1D Scientists and Clinicians
For scientists: This talk is a rare window into the process development side of cell therapy — the layer between elegant differentiation biology and actual clinical translation that rarely gets the spotlight it deserves. Dr. Dadheech details what changes when you move from research-grade to GMP-grade reagents (expansion rates can fall from 100-fold to under 10-fold), why serum composition alone can derail an entire batch, and why scale-up is emphatically non-linear. These are the practical realities that determine whether a promising protocol ever reaches a patient. The parallel exploration of muscle sheath as a retrievable, non-hepatic transplant site adds a complementary clinical dimension directly relevant to the stem cell therapy context.
For clinicians: The autologous iPSC model being developed at Upstate targets the fundamental limitation of current cell therapy — chronic immunosuppression and its cumulative toxicities. For T2D and pancreatogenic diabetes patients, a functionally mature autologous islet product manufactured from the patient’s own cells could be genuinely immunosuppression-free. For T1D, this remains an open challenge, but one the field is actively converging on through hypoimmune engineering and Treg-based strategies. A scalable GMP manufacturing platform is the prerequisite for all of these approaches reaching patients.
3️⃣ Big Takeaways
1. Vertical wheel bioreactors solve the scale problem that plates never could — but optimization is non-linear and far from finished. Moving from 0.1L to 0.5L already yields a 12-fold increase in islet equivalents from a single vessel, with no loss of beta cell identity, functional response to glucose, or endocrine purity. Projected to 3 liters, this platform could generate sufficient islet mass for a clinical transplant from one vessel, in 27 days. However, Dr. Dadheech is candid that scale-up is not plug-and-play: seeding density, shear stress, growth factor concentrations, and media composition all require reoptimization at each new volume. The 3-liter data are still pending — one of the field’s most important near-term manufacturing milestones.
2. Cellular heterogeneity is the hidden enemy of the entire iPSC-to-islet pipeline — and it starts at reprogramming, not differentiation. A central thrust of Dr. Dadheech’s new lab at Upstate is understanding why iPSC lines from different donors — healthy, T1D, T2D, pancreatogenic — produce such variable differentiation outcomes. His framework identifies heterogeneity sources across reprogramming, directed differentiation, culture format, and reagent grade, and proposes using single-cell omics, proteomics, and metabolic phenotyping to identify the driver biomarkers. If those biomarkers can be identified, they become quality control targets — and potentially therapeutic levers through small molecule correction or genetic editing before differentiation even begins.
3. Muscle sheath is emerging as a serious candidate for a retrievable, monitorable islet transplant site. Working with transplant collaborator Dr. Dilbasi, the Upstate team has demonstrated sustained C-peptide production and glucose control in diabetic mice transplanted under the gluteus maximus muscle sheath for up to 10 months — including with human donor islet cells. Unlike intraportal liver delivery, this site is retrievable if something goes wrong and imageable non-invasively by MRI, PET, or CT. With stem cell-derived islets still carrying theoretical off-target risks, a recoverable implant site is not a convenience — it is a safety requirement that could determine regulatory feasibility.
❓ Key Questions from the Discussion
How does scale-up affect beta cell function — and where does the data currently end? Functional beta cell identity, endocrine purity, and perifusion response have been maintained consistently from 30mL to 500mL across multiple donor lines including T1D patients. The 3-liter scale remains untested. Dr. Dadheech’s expectation is that major functional differences are unlikely, but he is explicit that this must be empirically demonstrated — and that GMP-grade reagent substitution alone can dramatically change cell behavior in ways not predictable from research-grade data.
Can hypoimmune gene editing strategies be integrated into this suspension manufacturing platform? Dr. Dadheech’s view is yes — and that several large pharma partners are already evaluating vertical wheel bioreactors for exactly this purpose. The process parameters will need optimization for gene-edited lines, but the suspension format itself is not a barrier. Given that hypoimmune iPSC lines represent the most likely near-term path to immunosuppression-free allogeneic therapy in T1D, the compatibility of this manufacturing platform with those genetic modifications is a critical strategic question with real near-term clinical urgency.
What are the regulatory and supply chain bottlenecks that could stall clinical translation? Two issues stand out. First, several small molecules and growth factors essential to current differentiation protocols are not available in GMP-certified form from any vendor — creating a compliance gap that requires FDA flexibility and careful documentation. Second, the transition from research-grade to clinical-grade media is not seamless; iPSC expansion rates can fall by an order of magnitude when switching to CTS-grade reagents. Both issues point to the same conclusion: the reagent supply chain must develop in parallel with the cell manufacturing protocols, not after them.
🔗 3 TSS Talks That Connect With This One
1. Sonja Schrepfer, MD PhD & Curtis Cetrulo, MD — Sana Biotech / Cedars Sinai TSS Think Tank The hypoimmune (HIP) platform from Sana represents exactly the immune evasion strategy Dr. Dadheech envisions pairing with his bioreactor manufacturing system. Dr. Schrepfer’s work on engineering iPSC-derived islets to evade both innate and adaptive immunity without immunosuppression is the immunologic complement to the manufacturing infrastructure being built at Upstate — and the two need each other to reach the clinic. ▶️ Watch here
2. Xin Chen, PhD — Stanford University TSS Think Tank Dr. Chen’s work on stem cell-derived islet engineering at Stanford directly addresses the functional maturity and heterogeneity challenges that Dr. Dadheech identifies as the central biological bottleneck of his platform. A strong scientific pairing for understanding what the cells coming out of the bioreactor need to do — and how to verify they are doing it. ▶️ Watch here
3. Matt Bochenek, PhD — MIT TSS Think Tank Dr. Bochenek’s research on extrahepatic transplant sites and encapsulation strategies maps directly onto the muscle sheath implant site being developed by the Upstate team. As stem cell-derived islets require retrievable, monitorable implant sites for safety and regulatory reasons, the biomaterials and site selection science explored in this talk is essential companion context. ▶️ Watch here